Is Alphatec Holdings (ATEC) Below Fair Value After A 60% Fall?

Alphatec Holdings stock has fallen about 60.2% year to date, yet its valuation checks still lean towards the shares looking cheap on several measures. This sets up a clear tension between weak price performance and a relatively supportive valuation profile.

• Year to date, the share price is down 60.2%, which signals that sentiment around Alphatec Holdings has been under pressure for an extended period.
• Expectations for the company’s ability to grow its spine surgery business can support the valuation, while any setbacks in execution or higher capital needs may limit how much investors are willing to pay for the stock.
• Alphatec Holdings currently passes 5 of 6 valuation checks. This means the broader set of metrics points to the stock looking inexpensive overall compared with its fundamentals, according to our value score.

The issue now is whether the recent share price weakness has already more than accounted for these risks, or if Alphatec Holdings still does not offer enough value to compensate for them.

Find out why Alphatec Holdings' -23.7% return over the last year is lagging behind its peers.

Does Alphatec Holdings Look Undervalued on Sales?

P/S is a useful yardstick for Alphatec Holdings because the company is currently loss making, so revenue gives a clearer anchor than earnings. On this measure, the stock trades at about 1.6x sales, which is below both the Medical Equipment industry average of roughly 2.8x and a peer group average of about 4.8x.

Based on a tailored fair P/S ratio of around 3.3x, which reflects Alphatec Holdings' sector, size and risk profile, the current multiple sits well under what this framework suggests as a reasonable level. That gap indicates the market is pricing Alphatec Holdings at a discount to its assessed revenue-based valuation, even after factoring in the business risks highlighted earlier.

On the P/S multiple, Alphatec Holdings stock currently appears undervalued relative to both its industry and its modelled fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

The Alphatec Holdings Narrative: What Would Justify Today's Price?

For Alphatec Holdings, Simply Wall St Narratives sit between the current valuation puzzle and the underlying story, spelling out which paths for future growth, margins and earnings would need to play out for the stock to be worth materially more or less than today's price. They are available on Simply Wall St's Community page. Instead of stopping at a single ratio or model output, Narratives outline the future conditions that figure depends on, so you can watch how the real business lines up with those assumptions over time.

One of the top community narratives on Alphatec Holdings: 48% undervalued

"Expanding surgeon adoption, strong same store sales growth, and increasing procedural volume signal Alphatec's ability to leverage the aging population and rising prevalence of spinal conditions..."

Read one of the top narratives on Alphatec Holdings

Do you think there's more to the story for Alphatec Holdings? Head over to our Community to see what others are saying!

The Bottom Line

Alphatec Holdings screens as undervalued on revenue multiples, with the current P/S ratio sitting below both industry peers and a tailored fair ratio. The broader valuation checks are relatively supportive, but they do not remove the execution and funding risks already flagged around the spine surgery growth plan. For investors, the crux is whether Alphatec Holdings can translate surgeon adoption and procedure volume into durable revenue and margin progress that eventually earns a higher multiple, or whether the current discount reflects the market’s view of the strain involved in that journey.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com